Patents by Inventor Philip H. Elzer
Philip H. Elzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8258100Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: June 19, 2009Date of Patent: September 4, 2012Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Publication number: 20100016227Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: ApplicationFiled: June 19, 2009Publication date: January 21, 2010Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHNICAL COLLEGEInventors: FREDERICK M. ENRIGHT, JESSE M. JAYNES, WILLIAM HANSEL, KENNETH L. KOONCE, SAMUEL M. MCCANN, WEN H. YU, PATRICIA A. MELROSE, LANE D. FOIL, PHILIP H. ELZER
-
Patent number: 7566777Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: July 11, 2003Date of Patent: July 28, 2009Assignee: Board of Supervisors of Louisana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Patent number: 7262163Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% ?,?-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar ?,?-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.Type: GrantFiled: April 14, 2003Date of Patent: August 28, 2007Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Mark L. McLaughlin, Thomas S. Yokum, Frederick M. Enright, Philip H. Elzer, Robert P. Hammer
-
Publication number: 20040059088Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% &agr;,&agr;-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar &agr;,&agr;-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.Type: ApplicationFiled: April 14, 2003Publication date: March 25, 2004Inventors: Mark L. McLaughlin, Thomas S. Yokum, Frederick M. Enright, Philip H. Elzer, Robert P. Hammer
-
Publication number: 20040018967Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: ApplicationFiled: July 11, 2003Publication date: January 29, 2004Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Patent number: 6680058Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) The two components—the ligand and the lytic peptide—may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide.Type: GrantFiled: February 22, 2000Date of Patent: January 20, 2004Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Patricia A. Melrose, Philip H. Elzer
-
Patent number: 6635740Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: September 24, 1999Date of Patent: October 21, 2003Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Patent number: 6566334Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% &agr;,&agr;-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar &agr;,&agr;-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.Type: GrantFiled: February 5, 1998Date of Patent: May 20, 2003Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Mark L. McLaughlin, Thomas S. Yokum, Frederick M. Enright, Philip H. Elzer, Robert P. Hammer